Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, controlled, open-label, 48-week study of continuing successfully suppressive treatment in HIV-1 infected adults with first-line twice-daily zidovudine and lamivudine-based regimens versus pro-actively replacing of zidovudine and lamivudine by once-daily emtricitabine and tenofovir disoproxil fumarate to prevent progression of or reverse peripheral lipoatrophy

Next Previous
Trial Profile

A randomized, controlled, open-label, 48-week study of continuing successfully suppressive treatment in HIV-1 infected adults with first-line twice-daily zidovudine and lamivudine-based regimens versus pro-actively replacing of zidovudine and lamivudine by once-daily emtricitabine and tenofovir disoproxil fumarate to prevent progression of or reverse peripheral lipoatrophy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/zidovudine
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms PREPARE

    • Most Recent Events

    • 08 Mar 2012 Results from a substudy assessing the effects of treatment on bone metabolism and bone mineral density presented at the 19th Conference on Retroviruses and Opportunistic Infections.
    • 02 Mar 2011 Results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
    • 10 Jun 2010 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top